- جمعه ٣٠ شهريور ١٣٩٧
صفحه اصلی > مجلات 


  چاپ        ارسال به دوست

Regenerative Medicine

 
Thomson Impact Factor: 2.602 (2015) | 20/76  Engineering, Biomedical; 16/21 Cell & Tissue Engineering
5- Year Impact Factor: 3.336
SJR: 0.754 (2014) | IPP: 2.29 (2014) | SNIP: 0.634 (2014)
Article Influence Score: 0.916
Eigenfactor Score: 0.00388 (EFn: 0.44130)

Aims and Scope

Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine (ISSN: 1746-0751) has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization.

Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community.

Regenerative Medicine exclusively supports all avenues that lead to the replacement or regeneration of human cells, tissue or organs, to restore or establish normal function. The sector is complex, rapidly evolving and multidisciplinary in nature, however, Regenerative Medicine is highly dynamic and has always embraced the progress made by the field and moved accordingly to support the critical issues including:

  • • Bench-to-bedside translation
  • • Tissue engineering and organ replacement
  • • Regenerative pharmacology
  • • Cell and gene therapy
  • • Regenerative nanotechnology
  • • Manufacturing and cost of goods
  • • Regulatory and reimbursement
  • • Ethical and legal perspectives
  • • Business models and commercialization
  • • Government policy

 

Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.

Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.

*Mason C, Dunnill P. A brief definition of regenerative medicine. Regenerative Medicine. 3(1), 1–5 (2008).

Indexing

Indexed in: Biological Abstracts; BIOSIS Previews; Biotechnology Citation Index®; Chemical Abstracts; EMBASE/Excerpta Medica; EMCare; Journal Citation Reports/Science Edition; MEDLINE/Index Medicus; Science Citation Index Expanded (SciSearch®); Scopus

Key Information

ISSN: 1746-0751

EISSN: 1746-076X

Current Volume: Volume 11 (2016)

Issues per Year: 8

Average Abstract Views: 11,702 (June 2015 - May 2016)

Open Access Option: Yes

Average Lead Time to Online Publication: 14 - 16 weeks

Rapid Publication Option: Yes


٠٨:٤٩ - پنج شنبه ٦ آبان ١٣٩٥    /    شماره : ٦٧٧    /    تعداد نمایش : ٢٢٧


نظرات بینندگان
این خبر فاقد نظر می باشد
نظر شما
نام :
ایمیل : 
*نظرات :
متن تصویر:
 

خروج




صفحه اصلیاخبار و تازه هامقالاتمجلاتتماس با مادرباره ما
طراحی شده توسط: آریانیک